Contact Us

*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 


Cell Phone 

Street Address 

Zip Code 



Date you started taking this drug:

Date you stopped taking this drug:

What condition was this medication prescribed to treat?

Did a heart attack occur within one year of taking Premphase or Prempro?

Were any of the following problems experienced during or after taking HRT medication?

If you suffered any of the above conditions, what was your age when diagnosed?

What was the date you were diagnosed with TTP?

Please describe diagnosis:

Please describe history of HRT drug prescriptions (please provide date and drug used in chronological order):

If diagnosed with breast cancer, please indicate details of diagnosis:

Have any family members (sisters, mother, grandmothers) been diagnosed with breast cancer?

If yes, please describe which family member was diagnosed and the type of cancer that was diagnosed:

Have you been genetically screened for breast cancer?

If you have been screened for breast cancer, please describe results:

Please describe history of blood clots and/or strokes:

Did you ever take Provera?

If yes, did you take Provera while taking Premphase or Premarin?

Please further describe side effects:

For verification purposes, please answer the below question:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Study Against Use of Hormones For Bones

Oct 1, 2003 | UPI

Hormone replacement therapy should not be prescribed solely to prevent bone-thinning osteoporosis, according to a study in the Women's Health Initiative.

The study, published in the Journal of the American Medical Association, says the benefit of preventing broken bones is not worth the risks of increased rates of heart disease, breast cancer, strokes and blood clots in the lungs.

The research disputes the policy of the Food and Drug Administration, which permits the use of Prempro, the combined hormone therapy of estrogen and progestin, a form of progesterone, to prevent osteoporosis, the New York Times reported.

FDA officials are scheduled to meet with researchers on Oct. 7 to evaluate the data on osteoporosis. An FDA spokeswoman said it was possible the approved uses of Prempro could change, the Times said.

The medical journal study is based on the same government study that compared 8,102 women who took placebos with 8,506 who took Prempro and found a small increase in the risk of breast cancer, the Times said.

Wyeth, the maker of Prempro, said decisions about hormone use should be made by women and their doctors.

Related articles
Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo